Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer Clinical Trial

Official title:

A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m^2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00661427
• Other study ID #: 08-039
• Status: Completed
• Phase: Phase 2
• First received: January 7, 2008
• Last updated: December 11, 2017
• Start date: November 2007
• Est. completion date: August 2012

Study information

• Verified date: December 2017
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well. Doses as high as 700 mg/m2 every other week appear to be no more toxic, so we will try to determine if 500 mg/m2 and 750 mg/m2 given every other week can work better. We do not know if it will help. We can use what we learn from this research study to help other people with the same disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• signed informed consent and HIPAA authorization

• histologically confirmed squamous cell cancer of the head and neck

• At least 21 days must have elapsed from the administration of prior chemotherapy for recurrent/metastatic disease.

• measurable disease as defined by RECIST

• ECOG PS = 2

• Adequate hematologic function as defined by an ANC > or = to 1200/mm3 , and a platelet count = 100,000 obtained within 14 days prior to enrollment.

• Adequate hepatic function as defined by t. bilirubin = 1.5 mg/dl, transaminases & alk phos = 5x ULN obtained within 14 days prior to enrollment.

• Adequate renal function as defined by serum creatinine = 1.5 x ULN or creatinine clearance >40 mL/minute.

• Women of childbearing potential must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study and have a negative pregnancy test within 7 days prior to registration. If a male and sexually active, the patient agrees to use effective contraception.

• Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.

• Patients with treated CNS metastases may be eligible if they have fully recovered from radiation therapy, surgery or steroids that were prescribed for CNS metastases.

Exclusion Criteria:

• Known, uncontrolled CNS metastases. CT/MRI of the brain is not required unless CNS metastases are suspected clinically.

• prior cetuximab therapy in the setting of recurrence or refractory disease

• Other active invasive malignancies, other than non-melanoma skin cancers or in situ cervical cancer.

• Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, or targeted therapy.

• Ongoing or active clinically serious infection > CTCAE Grade 2 requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia,(patients with stable rate-controlled atrial fibrillation may be eligible) or other medical condition that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study, or psychiatric illness/social situations that would limit compliance with study requirements.

• elective or planned major surgery to be performed during the course of the trial

• pregnant or lactating women

• employees of the investigator or study center w/ direct involvement in this study or other studies under the direction of the or study center, as well as family member of the employees

• More than two prior cytotoxic regimens for metastatic/recurrent disease.

• Known hypersensitivity reaction to mouse antibodies.

• Patients with nasopharyngeal cancer are excluded.

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck
• Neoplasms, Squamous Cell
• Squamous Cell Cancer

Intervention

Biological:
• cetuximab
Cetuximab 500 mg/m^2 IV over 2 hours every other week
• cetuximab
Cetuximab 750 mg/m^2 IV over 3 hours every other week

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center at Basking Ridge	Basking Ridge	New Jersey
United States	Memorial Sloan-Kettering Cancer Center at Commack	Commack	New York
United States	City of Hope National Medical Center	Duarte	California
United States	NorthShore University Health System	Evanston	Illinois
United States	University of Tennessee Cancer Institute	Memphis	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Abramson Cancer Center University of Pennsylvania	Philadelphia	Pennsylvania
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Fox Chase Virtua Health Cancer Program	Philadelphia	Pennsylvania
United States	Pennsylvania Hospital	Philadelphia	Pennsylvania
United States	University of Pennsylvania - Abramson Cancer Center	Philadelphia	Pennsylvania
United States	Memorial Sloan-Kettering at Mercy Medical Center	Rockville Centre	New York
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Huntsman Cancer Institue	Salt Lake City	Utah
United States	Memoral Sloan Kettering Cancer Center@Phelps	Sleepy Hollow	New York
United States	H. Lee Moffit Cancer Center and Research Institute	Tampa	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	ImClone LLC, National Comprehensive Cancer Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Overall Objective Response	Patients will be evaluated for response according to a modified version of the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Target lesions: Complete Response (CR): The disappearance of all target lesions. To be assigned a status of complete response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Partial Response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions,taking as reference the baseline sum longest diameter. To be assigned a status of partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify progressive disease. To be assigned a status of stable disease, taking as reference the smallest sum longest diam	Approximately every 8 weeks with imaging up to two years
Secondary	The Total Number of Participants That Were Effected by Adverse Events.	Terminology Criteria Version 3.0 or study specific toxicity tables provided in the protocol define severity.	at least weekly

External Links

•   Memorial Sloan-Kettering Cancer Center